Showing results (161-170 of 516) with videos related to
Sort By:
Pageof 52
The Journal of Antimicrobial Chemotherapy|June 22, 2019
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitalsMariana Castanheira, Timothy B Doyle, Caitlin J Smith, et al.The Journal of Antimicrobial Chemotherapy|January 3, 2018
Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16)Michael A Pfaller, Helio S Sader, Mariana Castanheira, et al.Journal of Global Antimicrobial Resistance|November 4, 2018
Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolatesSarah E Costello, Lalitagauri M Deshpande, Andrew P Davis, et al.Antimicrobial Agents and Chemotherapy|February 1, 2017
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.Diagnostic Microbiology and Infectious Disease|July 9, 2020
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteriaHelio S Sader, Mariana Castanheira, Jennifer M Streit, et al.Antimicrobial Agents and Chemotherapy|June 27, 2012
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec typesMariana Castanheira, Helio S Sader, David J Farrell, et al.International Journal of Antimicrobial Agents|February 14, 2024
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022)Helio S Sader, Cecilia G Carvalhaes, John H Kimbrough, et al.Microbiology Spectrum|October 10, 2024
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsJohn H Kimbrough, Joshua M Maher, Helio S Sader, et al.Antibiotics (Basel, Switzerland)|April 29, 2025
Characterization of Enterobacter cloacae and Citrobacter freundii Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-Avibactam and Comparator Agents (2019-2023)Helio S Sader, Timothy B Doyle, John H Kimbrough, et al.Antibiotics (Basel, Switzerland)|June 27, 2024
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and Pseudomonas aeruginosa from Intensive Care Unit and Non-Intensive Care Unit PatientsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.Pageof 52